Evidence map›Paper›PMID 25760776›Full record

ArticleBioconjugate chemistry2015

Click-chemistry strategy for labeling antibodies with copper-64 via a cross-bridged tetraazamacrocyclic chelator scaffold.

Amit Kumar, Guiyang Hao, Li Liu, Saleh Ramezani, Jer-Tsong Hsieh, Orhan K Öz, Xiankai Sun

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioconjugate chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. PET radiometals for antibody labeling.Journal of labelled compounds & radiopharmaceuticals · 2018
    Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Amit Kumar†Departments of Radiology and ‡Urology, and §Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States.
Guiyang Hao†Departments of Radiology and ‡Urology, and §Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States.
Li Liu†Departments of Radiology and ‡Urology, and §Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States.
Saleh Ramezani†Departments of Radiology and ‡Urology, and §Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States.
Jer-Tsong Hsieh†Departments of Radiology and ‡Urology, and §Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States.
Orhan K Öz†Departments of Radiology and ‡Urology, and §Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States.
Xiankai Sun†Departments of Radiology and ‡Urology, and §Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States.
Advanced Imaging Research (United States) · USThe University of Texas Southwestern Medical Center · US

Funding

Targeting aggressive prostate cancer with novel theranostic nanomedicineR01CA159144 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HSIEH, JER-TSONG · 2011 to 2015
$1.6M
NCI NIH HHS CA159144NCI NIH HHS R01 CA159144
6 · The paper itself

Abstract

We report a click-chemistry based modular strategy for antibody labeling with (64)Cu (t1/2 = 12.7 h; β(+) 0.656 MeV, 17.4%; β(-) 0.573 MeV, 39%; EC 43%) under ambient condition utilizing a cross-bridged tetraazamacrocyclic (CB-TE2A) analogue, which otherwise requires harsh conditions that make the CB-TE2A analogues under-utilized for protein labeling despite the fact that they form kinetically inert copper complexes with high in vivo stability. Our strategy involves prelabeling a CB-TE2A based scaffold (CB-TE2A-1C) with (64)Cu and its subsequent reaction with an antibody via the tetrazine-norbornene mediated click chemistry. The effectiveness of this strategy was demonstrated by labeling two monoclonal antibodies, an anti-PSMA antibody (YPSMA-1) and a chimeric anti-phosphatidylserine antibody (Bavituximab). The immunoreactivity of the antibodies remained unchanged after the tetrazine modification and click-chemistry (64)Cu labeling. To further demonstrate the practicality of the modular (64)Cu labeling strategy, we tested positron emission tomography (PET) imaging of tumor with the (64)Cu-labeled bavituximab in a mouse xenograft model. The tumor visualization and uptake of the labeled antibody exhibited the versatility of the click-chemistry strategy.

Indexed as

AdenocarcinomaAnimalsAntibodies, MonoclonalAntigens, SurfaceChelating AgentsClick ChemistryCopper RadioisotopesGene ExpressionGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingHumansMaleMicePositron-Emission TomographyProstatic NeoplasmsRadiopharmaceuticalsAntibodies, MonoclonalAntigens, SurfacebavituximabChelating AgentsCopper RadioisotopesFOLH1 protein, humanGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingRadiopharmaceuticals

Identifiers

PMID25760776
PMCPMC8374950
OpenAlexW1965454195

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.